Skip to main navigation Skip to search Skip to main content

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

  • Yafit Segman
  • , Elena Ribakovsky
  • , Abraham Avigdor
  • , Yair Goldhecht
  • , Vladimir Vainstein
  • , Neta Goldschmidt
  • , Shimrit Harlev
  • , Netanel Horwitz
  • , Odit Gutwein
  • , Ronit Gurion
  • , Gilad Itchaki
  • , Uri Abadi
  • , Anatoly Nemets
  • , Orit Sofer
  • , Miri Zektser
  • , Tamar Tadmor
  • , Nagib Dally
  • , Kalman Filanovsky
  • , Merav Leiba
  • , Nadav Sarid
  • Noam Benyamini, Yair Herishanu, Ron Ram, Chava Perry, Irit Avivi
  • Tel Aviv University
  • Hadassah University Medical Centre
  • Technion-Israel Institute of Technology
  • Assaf Harofeh Medical Center
  • Rabin Medical Center Israel
  • Meir Hospital Sapir Medical Center
  • Barzilai Medical Center
  • Hille Yaffe Medical Center Israel
  • Soroka Medical Center
  • Bnai-Zion Medical Center
  • Rebecca Sieff Government Hospital
  • Kaplan Medical Center Israel
  • Assuta Medical Center

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalLeukemia and Lymphoma
Volume62
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Lymphoma and Hodgkin disease
  • immunotherapeutic approaches
  • relapsed refractory DLBCL

Fingerprint

Dive into the research topics of 'Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience'. Together they form a unique fingerprint.

Cite this